Hassane M. Zarour

Hassane M. Zarour

Dermatology
5115 Centre Avenue, Hillman Cancer Center
Pittsburgh, PA 15232

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 62 publications

Toward a Dual-Axis Model of Microbiome Modulation in Cancer Immunotherapy: Pathobiont Elimination and Functional Ecosystem Restoration.

Toward a Dual-Axis Model of Microbiome Modulation in Cancer Immunotherapy: Pathobiont Elimination and Functional Ecosystem Restoration.

Journal: Cellular and molecular bioengineering
Published: July 10, 2026

Improving immunotherapy in solid tumors using FMT.

Improving immunotherapy in solid tumors using FMT.

Journal: Cell
Published: March 11, 2026

Harnessing the Microbiome in Cancer Immunotherapy: Regulation, Prediction, and Therapeutic Targeting.

Harnessing the Microbiome in Cancer Immunotherapy: Regulation, Prediction, and Therapeutic Targeting.

Journal: Annual review of immunology
Published: December 05, 2025

Multiregional CT Features Improve Prediction of Immunotherapy Response in Advanced Melanoma.

Multiregional CT Features Improve Prediction of Immunotherapy Response in Advanced Melanoma.

Journal: medRxiv : the preprint server for health sciences
Published: November 24, 2025

Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma.

Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma.

Journal: Journal for immunotherapy of cancer
Published: January 21, 2025

Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.

Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.

Journal: Cancer cell
Published: June 13, 2024

Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy.

Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy.

Journal: Cell
Published: May 23, 2024

Radiomic analysis of patient and inter-organ heterogeneity in response to immunotherapies and BRAF targeted therapy in metastatic melanoma.

Radiomic analysis of patient and inter-organ heterogeneity in response to immunotherapies and BRAF targeted therapy in metastatic melanoma.

Journal: medRxiv : the preprint server for health sciences
Published: May 07, 2024

Automated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immunotherapy.

Automated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immunotherapy.

Journal: The oncologist
Published: January 04, 2024

Melanoma and microbiota: Current understanding and future directions.

Melanoma and microbiota: Current understanding and future directions.

Journal: Cancer cell
Published: October 10, 2023

Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.

Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.

Journal: Journal for immunotherapy of cancer
Published: September 07, 2023

Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.

Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.

Journal: bioRxiv : the preprint server for biology
Published: September 04, 2023
Showing 1-12 of 62

Last Updated: 09/26/2026